Common Contracts
333 similar Underwriting Agreement contracts by Aurora Innovation, Inc., Immatics N.V., Kodiak Gas Services, Inc., others
Oklo Inc. Class A Common Stock, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • June 16th, 2025 • Oklo Inc. • Electric services
Oklo Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 6,666,667 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 1,000,000 additional shares (the “Optional Shares”) of Class A Common Stock, par value $0.0001 per share (“Stock”) of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
QXO, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • April 21st, 2025 • QXO, Inc. • Services-computer processing & data preparation
Morgan Stanley & Co. LLC Goldman Sachs & Co. LLC As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto,
Sionna Therapeutics, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • February 3rd, 2025 • Sionna Therapeutics, Inc. • Pharmaceutical preparations
Atlas Energy Solutions Inc. Common Stock Underwriting AgreementUnderwriting Agreement • February 3rd, 2025 • Atlas Energy Solutions Inc. • Crude petroleum & natural gas
Atlas Energy Solutions Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 11,500,000 shares of its common stock, par value $0.01 per share (the “Firm Shares”) and, at the election of the Underwriters, up to 1,725,000 additional shares (the “Optional Shares”) of common stock of the Company (the “Stock”). The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares.”
Odyssey Therapeutics, Inc. Common Stock, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • January 17th, 2025 • Odyssey Therapeutics, Inc. • Biological products, (no disgnostic substances)
Amylyx Pharmaceuticals, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • January 10th, 2025 • Amylyx Pharmaceuticals, Inc. • Pharmaceutical preparations
Amylyx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 17,142,857 shares of common stock, par value $0.0001 per share (“Stock”), of the Company (the “Firm Shares”). In addition, the Company has granted the Underwriters an option to purchase, at the election of the Underwriters, up to 2,571,428 additional shares (the “Optional Shares”) of Stock (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”). To the extent there are no additional Underwriters listed on Schedule I other than the Representative, the term Underwriters shall mean either the singular or plural as the context requires.
uniQure N.V. 4,411,764 Ordinary Shares Underwriting AgreementUnderwriting Agreement • January 8th, 2025 • uniQure N.V. • Pharmaceutical preparations
uniQure N.V., a Dutch public company with limited liability (naamloze vennootschap) (the “Company”), proposes, subject to the terms and conditions stated in this underwriting agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 4,411,764 shares (the “Firm Shares”) of the Company’s ordinary shares, nominal value €0.05 per share (the “Ordinary Shares”). In addition, the Company has granted to the Underwriters an option to purchase up to 661,764 additional Ordinary Shares (the “Optional Shares”). The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Shares.”
ServiceTitan, Inc. Class A Common Stock Underwriting AgreementUnderwriting Agreement • December 3rd, 2024 • ServiceTitan, Inc. • Services-prepackaged software
Underwriting AgreementUnderwriting Agreement • December 2nd, 2024 • Amer Sports, Inc. • Apparel & other finishd prods of fabrics & similar matl
Amer Sports, Inc., an exempted company incorporated under the laws of the Cayman Islands with limited liability (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [ · ] shares (the “Firm Shares”) and, at the election of the Underwriters, up to [ · ] additional shares (the “Optional Shares”) of the Company’s ordinary shares, par value EUR 0.0300580119630888 per share (the “Ordinary Shares”). The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are collectively called the “Shares.”
Immatics N.V. Ordinary Shares (Nominal value €0.01 per share) Underwriting AgreementUnderwriting Agreement • October 15th, 2024 • Immatics N.V. • Biological products, (no disgnostic substances)
Immatics N.V., a public limited company (naamloze vennootschap) under Dutch law (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 16,250,000 (the “Firm Shares”) of the Company’s ordinary shares, nominal value €0.01 per share (“Ordinary Shares”), and, at the election of the Underwriters, up to 2,437,500 additional Ordinary Shares (the “Optional Shares”). The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are collectively referred to as the “Shares.”
BioAge Labs, Inc. Common Stock, par value $0.00001 per share Underwriting AgreementUnderwriting Agreement • September 18th, 2024 • BioAge Labs, Inc. • Pharmaceutical preparations
Aurora Innovation, Inc. Class A Common Stock, par value $0.00001 Underwriting AgreementUnderwriting Agreement • August 1st, 2024 • Aurora Innovation, Inc. • Services-computer integrated systems design
Aurora Innovation, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 116,666,667 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 17,500,000 additional shares (the “Optional Shares”) of Class A Common Stock, par value $0.00001 (“Class A Common Stock”) of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
WEBTOON Entertainment Inc. Common Stock, par value $0.0001 per share Form of Underwriting AgreementUnderwriting Agreement • May 31st, 2024 • WEBTOON Entertainment Inc. • Miscellaneous publishing
WEBTOON Entertainment Inc. a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of shares (the “Firm Shares”) and, at the election of the Underwriters, up to additional shares (the “Optional Shares”) of common stock, par value $0.0001 per share (the “Stock”) of the Company. The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Shares”.
Class A Common Stock Underwriting AgreementUnderwriting Agreement • April 16th, 2024 • Rubrik, Inc. • Services-prepackaged software
Rubrik, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [ • ] shares (the “Firm Shares”) and, at the election of the Underwriters, up to [ • ] additional shares (the “Optional Shares”) of Class A Common Stock, par value $0.000025 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Gritstone bio, Inc. 8,333,333 Shares of Common Stock, par value $0.0001 per share Pre-Funded Warrants to Purchase 13,334,222 Shares of Common Stock Common Warrants to Purchase 21,667,555 Shares of Common Stock (or Pre-Funded Warrants in Lieu Thereof)...Underwriting Agreement • April 2nd, 2024 • Gritstone Bio, Inc. • Biological products, (no disgnostic substances)
Contineum Therapeutics, Inc. (a Delaware corporation) [•] Shares of Class A Common Stock Underwriting AgreementUnderwriting Agreement • April 1st, 2024 • Contineum Therapeutics, Inc. • Pharmaceutical preparations
Contineum Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [•] shares (the “Firm Shares”) and, at the election of the Underwriters, up to [•] additional shares (the “Optional Shares”) of Class A Common Stock, par value $0.001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
NOTICE REGARDING UNDERWRITING AGREEMENTUnderwriting Agreement • March 27th, 2024 • Terreno Realty Corp • Real estate
The attached Underwriting Agreement is a contractual document that establishes and governs the legal relations among the parties with respect to the transactions described therein. The Underwriting Agreement is not intended to be a source for investors of factual, business, or operational information about the Company. The representations and warranties, covenants and agreements contained in the Underwriting Agreement were made only for purposes of the Underwriting Agreement, were solely for the benefit of the parties to the Underwriting Agreement, and may be subject to limitations agreed among those parties. Accordingly, investors and security holders should not rely on representations or warranties, covenants and agreements as characterizations of the actual state of facts or condition of the Company.
Boundless Bio, Inc. Common Stock, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • March 21st, 2024 • Boundless Bio, Inc. • Pharmaceutical preparations
Boundless Bio, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [•] shares (the “Firm Shares”) and, at the election of the Underwriters, up to [•] additional shares (the “Optional Shares”) of common stock, par value $0.0001 per share (“Stock”), of the Company. The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Shares.”
Arcutis Biotherapeutics, Inc. Common Stock, Par Value $0.0001 per Share Underwriting AgreementUnderwriting Agreement • March 4th, 2024 • Arcutis Biotherapeutics, Inc. • Pharmaceutical preparations
Rekor Systems, Inc. Common Stock, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • February 9th, 2024 • Rekor Systems, Inc. • Communications equipment, nec
Rekor Systems, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) for whom William Blair & Company, L.L.C. is acting as representative (the “Representative” or “you”) an aggregate of 10,000,000 shares (the “Firm Securities”) and, at the election of the Underwriters, up to 1,500,000 additional shares (the “Optional Securities”) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company (the Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Securities”). To the extent that you are the only Underwriter, all references to “each Underwriter,” “the Underwriters” or “Representative” shall refer to just you.
Sagimet Biosciences Inc. Series A Common Stock, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • January 23rd, 2024 • Sagimet Biosciences Inc. • Pharmaceutical preparations
Sagimet Biosciences Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”) and in the manner contemplated by this Agreement, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [●] shares (the “Firm Shares”) and, at the election of the Underwriters, up to [●] additional shares (the “Optional Shares”) of Series A common stock, par value $0.0001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
ArriVent BioPharma, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • January 22nd, 2024 • ArriVent Biopharma, Inc. • Pharmaceutical preparations
Goldman Sachs & Co. LLC Jefferies LLC Citigroup Global Markets Inc. As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto,
Immatics N.V. Ordinary Shares (Nominal value €0.01 per share) Underwriting AgreementUnderwriting Agreement • January 22nd, 2024 • Immatics N.V. • Biological products, (no disgnostic substances)
Immatics N.V., a public limited company (naamloze vennootschap) under Dutch law (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 15,925,000 (the “Firm Shares”) of the Company’s ordinary shares, nominal value €0.01 per share (“Ordinary Shares”), and, at the election of the Underwriters, up to 2,388,750 additional Ordinary Shares (the “Optional Shares”). The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are collectively referred to as the “Shares.”
Myriad Genetics, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • November 13th, 2023 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances
Myriad Genetics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 6,470,588 shares (the “Firm Securities”) and, at the election of the Underwriters, up to 970,588 additional shares (the “Optional Securities”) of common stock, par value $0.01 per share (“Stock”) of the Company (the Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Securities”).
MADRIGAL PHARMACEUTICALS, INC. 1,248,098 Shares of Common Stock, par value $0.0001 per share Pre-Funded Warrants to Purchase 2,048,098 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • October 2nd, 2023 • Madrigal Pharmaceuticals, Inc. • Pharmaceutical preparations
Madrigal Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) (i) an aggregate of 1,248,098 shares (the “Firm Shares”) of the Company’s common stock, $0.0001 par value (the “Common Stock”), and (ii) warrants of the Company to purchase 2,048,098 shares of Common Stock at an exercise price equal to $0.0001 per share (the “Pre-Funded Warrants” and, together with the Firm Shares, the “Firm Securities”). As used herein, “Warrant Shares” means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants. In addition, the Company has granted to the Underwriters an option to purchase up to 494,429 additional shares of Common Stock (the “Optional Shares”). The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called t
Underwriting AgreementUnderwriting Agreement • August 14th, 2023 • Innoviz Technologies Ltd. • Motor vehicle parts & accessories
Innoviz Technologies Ltd., a company organized under the laws of the State of Israel (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 26,000,000 ordinary shares, no par value per share, of the Company (the “Firm Shares”) and, at the election of the Underwriters, up to 3,900,000 additional ordinary shares, no par value per share, of the Company (the “Optional Shares”). The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”.
Flywire Corporation Common Stock Underwriting AgreementUnderwriting Agreement • August 11th, 2023 • Flywire Corp • Services-business services, nec
Flywire Corporation, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 8,000,000 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 1,200,000 additional shares (the “Optional Shares”) of voting common stock, $0.0001 par value per share (“Stock”) of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Aurora Innovation, Inc. Class A Common Stock, par value $0.00001 Underwriting AgreementUnderwriting Agreement • July 19th, 2023 • Aurora Innovation, Inc. • Services-computer integrated systems design
Aurora Innovation, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 73,333,333 shares the “Firm Shares”) and, at the election of the Underwriters, up to 10,999,999 additional shares (the “Optional Shares”) of Class A Common Stock, par value $0.00001 (“Class A Common Stock”) of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Kodiak Gas Services, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • July 5th, 2023 • Kodiak Gas Services, Inc. • Natural gas transmission
Kodiak Gas Services Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 16,000,000 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 2,400,000 additional shares (the “Optional Shares”) of common stock (“Stock”) of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Sagimet Biosciences Inc. Series A Common Stock, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • July 3rd, 2023 • Sagimet Biosciences Inc. • Pharmaceutical preparations
Sagimet Biosciences Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”) and in the manner contemplated by this Agreement, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [●] shares (the “Firm Shares”) and, at the election of the Underwriters, up to [●] additional shares (the “Optional Shares”) of Series A common stock, par value $0.0001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Phathom Pharmaceuticals, Inc. Common Stock, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • May 24th, 2023 • Phathom Pharmaceuticals, Inc. • Pharmaceutical preparations
Phathom Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as representatives (the “Representatives”) an aggregate of 11,125,000 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 1,668,750 additional shares (the “Optional Shares”) of common stock, par value $0.0001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
DUCOMMUN INCORPORATED Common Stock, par value $.01 per share Underwriting AgreementUnderwriting Agreement • May 18th, 2023 • Ducommun Inc /De/ • Aircraft parts & auxiliary equipment, nec
Ducommun Incorporated, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 2,000,000 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 300,000 additional shares (the “Optional Shares”) of common stock, par value $.01 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
4D Molecular Therapeutics, Inc. Common Stock, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • May 9th, 2023 • 4D Molecular Therapeutics, Inc. • Biological products, (no disgnostic substances)
4D Molecular Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as representatives (the “Representatives”) an aggregate of 7,500,000 shares of common stock, par value $0.0001 per share (“Stock”), of the Company (the “Firm Shares”) and, at the election of the Underwriters, up to 1,125,000 additional shares of Stock (the “Optional Shares”) (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”). In the event that the Company has a single subsidiary or does not have any subsidiaries, then all references herein to “subsidiaries” of the Company shall be deemed to refer to such single subsidiary or to the Company, respectively, mutatis mutandis.
Kodiak Gas Services, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • March 31st, 2023 • Kodiak Gas Services, Inc. • Natural gas transmission
Kodiak Gas Services Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [ ⚫ ] shares (the “Firm Shares”) and, at the election of the Underwriters, up to [ ⚫ ] additional shares (the “Optional Shares”) of common stock (“Stock”) of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
VIKING THERAPEUTICS, INC. Common Stock, par value $0.00001 per share Underwriting AgreementUnderwriting Agreement • March 31st, 2023 • Viking Therapeutics, Inc. • Pharmaceutical preparations
Viking Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) for whom William Blair & Company, L.L.C. is acting as representative (the “Representative” or “you”) an aggregate of 17,242,000 shares (the “Firm Securities”) and, at the election of the Underwriters, up to 2,586,300 additional shares (the “Optional Securities”) of common stock, par value $0.00001 per share (the “Common Stock”), of the Company (the Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Securities”). To the extent that you are the only Underwriter, all references to “each Underwriter,” “the Underwriters” or “Representative” shall refer to just you.